Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

BACKGROUND: Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Della Corte, Carminia, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, Martinelli, Erika
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7789007/
https://ncbi.nlm.nih.gov/pubmed/33407715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01811-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados